‘Lung adenocarcinoma’, formerly a solitary entity in the histology-based categorization of non–small-cell lung cancer , now represents an ever-expanding list of diseases defined by molecular drivers.
. Targeted therapeutics for this disease have seen variable success, with the antibody–drug conjugate trastuzumab deruxtecan and various others, such as the tyrosine kinase inhibitor pyrotinib, demonstrating promising efficacy in early-phase trials
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WIRED - 🏆 555. / 51 Read more »